The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

The company said that envudeucitinib met all the primary and secondary endpoints in both trials. ・Across both trials, the ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

As of January 29, 2025, the average one-year price target for Alumis is $30.60/share. The forecasts range from a low of $25.25 to a high of $39.90. The average price target represents an increase of ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of $32 on Thursday, noting that despite the potential in its pipeline, the ...